Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Beyond semaglutide and tirzepatide, where might we find the next GLP 1 based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Weight Loss of 10% Within 2 Weeks? Evaluating Amylin Analogs in Diet Induced Obese (DIO) Rat Model_GemPharmatech